Cell Reports (Aug 2023)

Astrocytic response mediated by the CLU risk allele inhibits OPC proliferation and myelination in a human iPSC model

  • Zhenqing Liu,
  • Jianfei Chao,
  • Cheng Wang,
  • Guihua Sun,
  • Daniel Roeth,
  • Wei Liu,
  • Xianwei Chen,
  • Li Li,
  • E Tian,
  • Lizhao Feng,
  • Hayk Davtyan,
  • Mathew Blurton-Jones,
  • Markus Kalkum,
  • Yanhong Shi

Journal volume & issue
Vol. 42, no. 8
p. 112841

Abstract

Read online

Summary: The C allele of rs11136000 variant in the clusterin (CLU) gene represents the third strongest known genetic risk factor for late-onset Alzheimer’s disease. However, whether this single-nucleotide polymorphism (SNP) is functional and what the underlying mechanisms are remain unclear. In this study, the CLU rs11136000 SNP is identified as a functional variant by a small-scale CRISPR-Cas9 screen. Astrocytes derived from isogenic induced pluripotent stem cells (iPSCs) carrying the “C” or “T” allele of the CLU rs11136000 SNP exhibit different CLU expression levels. TAR DNA-binding protein-43 (TDP-43) preferentially binds to the “C” allele to promote CLU expression and exacerbate inflammation. The interferon response and CXCL10 expression are elevated in cytokine-treated C/C astrocytes, leading to inhibition of oligodendrocyte progenitor cell (OPC) proliferation and myelination. Accordingly, elevated CLU and CXCL10 but reduced myelin basic protein (MBP) expression are detected in human brains of C/C carriers. Our study uncovers a mechanism underlying reduced white matter integrity observed in the CLU rs11136000 risk “C” allele carriers.

Keywords